Panacea Biotec Ltd (PANACEABIO) — shareholding pattern, promoter holding, financials and share price
About Panacea Biotec Ltd (PANACEABIO)
Panacea Biotec Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PANACEABIO and on the BSE under scrip code 531349. Its ISIN is INE922B01023.
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company [1]
Panacea Biotec Limited is India's second largest vaccine producer and a research-based health management company, specializing in prescription products across various therapeutic areas.
The company has a strong R&D background with collaborations with both national and international research organizations, and it holds product patents in multiple countries.
Listed peers in Pharmaceuticals: SMS Pharmaceuticals Ltd, Novartis India Ltd, Aarti Drugs Ltd, Morepen Laboratories Ltd, Dishman Carbogen Amcis Ltd, Hikal Ltd.
Valuation & Returns
10 Jul 2026At ₹546.25 a share on 10 Jul 2026, Panacea Biotec Ltd (PANACEABIO) was valued at a price-to-earnings ratio of -623.46x against an industry P/E of 36.41x and a price-to-book of 4.01x on a book value of ₹136.29 per share as of Mar 2025. Solomo computes return on equity of -0.86% and return on capital employed of -0.15% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -623.46x
- Industry P/E
- 36.41x
- P/B
- 4.01x
- EPS (TTM)
- ₹-1.17
- Book value / share
- ₹136.29
- ROE
- -0.86%
- ROCE
- -0.15%
- ROA
- -0.56%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- 4.96%
- 52-week range
- ₹293.1 – ₹647.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Panacea Biotec Ltd (PANACEABIO) reported revenue of ₹640 crore, net profit of ₹-7 crore and earnings per share of ₹-0.88. That compares with revenue of ₹559 crore and net profit of ₹-9 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹166.75 crore and net profit ₹-1 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 661 | 460 | 559 | 559 | 640 |
| Net profit (₹ cr) | 1,078 | -34 | -2 | -9 | -7 |
| EPS (₹) | 175.91 | -5.42 | -0.19 | -1.37 | -0.88 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -7.86% | 14.41% | 9.58% | -0.01% |
| Profit growth | - | - | - | 477.48% |
| Stock price CAGR | 16% | 9% | 65% | 30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.48% of Panacea Biotec Ltd (PANACEABIO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.31% and domestic institutional investors (DII) hold 2.25%. Market capitalisation was ₹3,346 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Massachusetts Institute of Technology 1.71%, Viral Amal Parikh 1.47%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.48% | - | 2.31% | 2.25% | 27.52% |
| Mar 2026 | 72.48% | - | 1.6% | 1.97% | 27.52% |
| Dec 2025 | 72.48% | - | 1.36% | 1.85% | 27.52% |
| Sep 2025 | 72.48% | - | 1.06% | 1.81% | 27.52% |
| Jun 2025 | 72.48% | - | 0.78% | 1.52% | 27.52% |
| Mar 2025 | 72.48% | - | 1.16% | 1.49% | 27.52% |
| Dec 2024 | 72.49% | - | 0.38% | 1.17% | 27.51% |
| Sep 2024 | 72.87% | - | 0.37% | 1.16% | 27.13% |